Wellbutrin (Bupropion) Dose Adjustments
Yes, Wellbutrin requires dose adjustments in patients with renal or hepatic impairment, but no adjustment is needed in those with normal organ function.
Renal Impairment Dosing
For patients with any degree of renal impairment (GFR <90 mL/min), consider reducing the dose and/or frequency of Wellbutrin 1. The FDA label explicitly states this applies to all patients with GFR below 90 mL/min, not just severe impairment 1.
Why Dose Reduction Matters in Renal Impairment
Bupropion and its active metabolites are cleared renally and accumulate significantly in renal impairment 1, 2. Research demonstrates that in renally impaired patients:
- Bupropion AUC increases by 126% 2
- Half-life extends by 140% 2
- Clearance decreases by 63% 2
- The metabolites (hydroxybupropion and threohydrobupropion) show marked accumulation 2, 3
A critical pitfall: While bupropion itself accumulates moderately, the active metabolites accumulate substantially more, and these metabolites possess similar pharmacological activity to the parent compound 2, 3. This means toxicity risk increases even if bupropion levels seem acceptable.
Specific Renal Dosing Recommendations
For severe renal impairment (GFR <30 mL/min):
- Naltrexone ER/bupropion ER is not recommended 4
- If using bupropion monotherapy, one study suggests 150 mg every 3 days may be more appropriate than daily dosing in hemodialysis patients 3
For moderate renal impairment (GFR 30-49 mL/min):
- When using naltrexone ER/bupropion ER combination, maximum dose should not exceed 8 mg/90 mg twice daily 4
For mild renal impairment (GFR 50-79 mL/min):
- Use with appropriate caution and consider dose reduction 4
Monitor closely for adverse reactions that could indicate high bupropion or metabolite exposures 1. Elderly patients are particularly vulnerable as they are more likely to have decreased renal function 1.
Hepatic Impairment Dosing
For moderate to severe hepatic impairment (Child-Pugh score 7-15), the maximum Wellbutrin XL dose is 150 mg every other day 1.
For mild hepatic impairment (Child-Pugh score 5-6), consider reducing the dose and/or frequency 1.
When using naltrexone ER/bupropion ER in moderate hepatic impairment, the maximum dose is 1 tablet (8 mg/90 mg) in the morning 4, 5.
Rationale for Hepatic Dose Adjustment
Bupropion is extensively metabolized in the liver 1. The risk of adverse reactions increases substantially in hepatic impairment due to reduced drug clearance and potential accumulation of both parent drug and active metabolites.
Normal Organ Function
No dose adjustment is required in patients with normal renal and hepatic function. Standard dosing applies:
- MDD: Start 150 mg once daily, may increase to 300 mg once daily after 4 days 1
- SAD: Start 150 mg once daily, may increase to 300 mg once daily after 7 days 1
Key Clinical Considerations
Common pitfall: The 2016 AACE/ACE obesity guidelines note that naltrexone ER/bupropion ER should be avoided with fatty meals, as this significantly increases systemic drug levels 5. This applies regardless of renal or hepatic function.
Drug interactions: Bupropion levels can be affected by P-glycoprotein inhibitors, and the combination product should be used cautiously with beta-blockers as it may increase beta-blocker levels 5.
Seizure risk: The dose must be increased gradually to minimize seizure risk, which is the primary safety concern with bupropion 1. This is particularly important in patients with impaired clearance.